open access

Vol 66, No 3 (2016)
Review paper
Published online: 2016-07-12
Get Citation

Urological oncology: what has changed in the recent 25 years?

Paweł Stajno, Paweł Wiechno, Tomasz Demkow
·
Nowotwory. Journal of Oncology 2016;66(3):238-244.

open access

Vol 66, No 3 (2016)
Review article
Published online: 2016-07-12

Abstract

A considerable progress in the diagnosis and treatment of urinary tract cancers in the last 25 years is observed. A short review of this process is presented, together with the epidemiological data on most frequent cancer locations. Multiparametric magnetic resonance allows for an improved detection of small prostate cancers and more precise resection; this may be combined with ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging. Prostate cancer gene 3 (PCA3) is a new prostate cancer cell-specific marker. A “watchful waiting” method of deferred treatment is now substituted by “active surveillance”. 3-Dimensional Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Image-Guided Radiation Therapy and other techniques facilitate more precise and dose-increased prostate cancer irradiation. Despite the implementation of new techniques in bladder cancer detection, like photodynamic diagnosis and narrow band imaging, overall treatment results remain poor. Due to the progress of imaging techniques c. 50% of new renal cancer cases are now randomly detected and may be treated by nephron sparing surgery. The population of young men, cured definitely from testicular cancer, due to the excellent overall treatment results, is increasing; this requires more attention attributed to their social (i.e. reproductive) problems.

Abstract

A considerable progress in the diagnosis and treatment of urinary tract cancers in the last 25 years is observed. A short review of this process is presented, together with the epidemiological data on most frequent cancer locations. Multiparametric magnetic resonance allows for an improved detection of small prostate cancers and more precise resection; this may be combined with ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging. Prostate cancer gene 3 (PCA3) is a new prostate cancer cell-specific marker. A “watchful waiting” method of deferred treatment is now substituted by “active surveillance”. 3-Dimensional Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Image-Guided Radiation Therapy and other techniques facilitate more precise and dose-increased prostate cancer irradiation. Despite the implementation of new techniques in bladder cancer detection, like photodynamic diagnosis and narrow band imaging, overall treatment results remain poor. Due to the progress of imaging techniques c. 50% of new renal cancer cases are now randomly detected and may be treated by nephron sparing surgery. The population of young men, cured definitely from testicular cancer, due to the excellent overall treatment results, is increasing; this requires more attention attributed to their social (i.e. reproductive) problems.

Get Citation

Keywords

prostate cancer, renal cancer, bladder cancer, testicular cancer, progress

About this article
Title

Urological oncology: what has changed in the recent 25 years?

Journal

Nowotwory. Journal of Oncology

Issue

Vol 66, No 3 (2016)

Article type

Review paper

Pages

238-244

Published online

2016-07-12

Page views

1099

Article views/downloads

5137

DOI

10.5603/NJO.2016.0040

Bibliographic record

Nowotwory. Journal of Oncology 2016;66(3):238-244.

Keywords

prostate cancer
renal cancer
bladder cancer
testicular cancer
progress

Authors

Paweł Stajno
Paweł Wiechno
Tomasz Demkow

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl